Krystal Biotech, Inc.

KRYS 10-K · FY 2025
API behind this page

KRYS FY 2025 request

Playground key active
Request URL /api/financials?ticker=KRYS&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue 389,130 290,515 +33.9%
Cost Of Goods And Services Sold Operating 23,049 20,061 +14.9%
Research & Development 58,045 53,580 +8.3%
Show Business Segments breakouts
Reportable Segment 58,045 53,580 +8.3%
Reportable Segment · B-VEC 6,690 8,760 -23.6%
Reportable Segment · KB111 1,837 — —
Reportable Segment · KB301 184 635 -71.0%
Reportable Segment · KB304 960 1,342 -28.5%
Reportable Segment · KB407 1,805 1,877 -3.8%
Reportable Segment · KB408 882 1,630 -45.9%
Reportable Segment · KB707 10,856 8,677 +25.1%
Reportable Segment · KB801 2,175 1,314 +65.5%
Reportable Segment · KB803 2,564 604 +324.5%
Reportable Segment · Other dermatology programs 12 935 -98.7%
Reportable Segment · Other ophthalmology programs 44 554 -92.1%
Reportable Segment · Other programs 2,493 2,098 +18.8%
Reportable Segment · Other research and development costs 27,543 25,154 +9.5%
Selling, General & Administrative 146,741 113,626 +29.1%
Show Business Segments breakouts
Reportable Segment 146,741 113,626 +29.1%
Operating Expenses 227,835 224,767 +1.4%
Operating Income 161,295 65,748 +145.3%
Show Business Segments breakouts
Reportable Segment 161,295 65,748 +145.3%
Interest Income Expense Nonoperating Net 28,176 29,608 -4.8%
Show Business Segments breakouts
Reportable Segment 28,176 29,608 -4.8%
Income Before Taxes 189,471 95,356 +98.7%
Show Business Segments breakouts
Reportable Segment 189,471 95,356 +98.7%
Show Income Tax Authority breakouts
Domestic Country 187,938 93,808 +100.3%
Foreign Country 1,533 1,548 -1.0%
Income Tax Expense (Benefit) 15,360 -6,197 +347.9%
Show Business Segments breakouts
Reportable Segment 15,360 -6,197 +347.9%
Net Income 204,831 89,159 +129.7%
Show Business Segments breakouts
Reportable Segment 204,831 89,159 +129.7%
Show Equity Components breakouts
Retained Earnings 204,831 89,159 +129.7%
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 642 -440 +245.9%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 642 -440 +245.9%
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent 684 -388 +276.3%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 684 -388 +276.3%
Comprehensive Income 206,157 88,331 +133.4%
EPS (Basic) 7.08 3.12 +126.9%
EPS (Diluted) 6.84 3 +128.0%
Wtd Avg Shares (Basic) 28,944 28,592 +1.2%
Wtd Avg Shares (Diluted) 29,951 29,740 +0.7%
Gross Profit (FY) — — —
Show Business Segments breakouts
Reportable Segment 366,081 270,454 +35.4%
Professional Fees (FY) — — —
Show Supply Commitment breakouts
Clinical Supply Agreements 9.3 7.1 +31.0%
Foreign Currency Transaction Gain Loss Before Tax 1.2 — —

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents 496,304 344,865 +43.9%
Show Fair Value Hierarchy breakouts
Fair Value Inputs Level1 · Cash 496,304 344,865 +43.9%
Available For Sale Securities Debt Securities Current 331,487 252,652 +31.2%
Accounts Receivable 127,425 104,746 +21.7%
Inventory 40,475 26,508 +52.7%
Prepaid Taxes 14,006 1,617 +766.2%
Prepaid Expenses & Other Current Assets 14,905 11,657 +27.9%
Total Current Assets 1,024,602 742,045 +38.1%
Non-Current Assets
Property, Plant & Equipment 150,776 155,168 -2.8%
Long Term Investments 128,066 152,114 -15.8%
Operating Lease Right-of-Use Assets 7,239 6,280 +15.3%
Deferred Tax Assets 22,824 — —
Other Non-Current Assets 287 231 +24.2%
Total Assets 1,333,794 1,055,838 +26.3%
Current Liabilities
Accounts Payable 3,238 4,985 -35.0%
Operating Lease Liability Current 1,771 1,217 +45.5%
Accrued Rebates Current 58,181 36,804 +58.1%
Accounts Payable And Other Accrued Liabilities Current 39,752 58,989 -32.6%
Total Current Liabilities 102,942 101,995 +0.9%
Non-Current Liabilities
Operating Lease Liabilities 7,568 6,044 +25.2%
Other Non-Current Liabilities 3,724 1,419 +162.4%
Total Liabilities 114,234 109,458 +4.4%
Stockholders' Equity
Additional Paid-In Capital 1,194,261 1,127,238 +5.9%
Accumulated Other Comprehensive Income 1,136 -190 +697.9%
Retained Earnings 24,163 -180,668 +113.4%
Total Stockholders' Equity 1,219,560 946,380 +28.9%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 1,136 -190 +697.9%
Additional Paid In Capital 1,194,261 1,127,238 +5.9%
Retained Earnings 24,163 -180,668 +113.4%
Total Liabilities & Equity 1,333,794 1,055,838 +26.3%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Increase Decrease In Deferred Income Taxes -22,845 — —
Depreciation 5,724 5,967 -4.1%
Accretion Expense Net -498 -1,706 +70.8%
Operating Lease Right Of Use Asset Amortization Expense 827 747 +10.7%
Stock-Based Compensation 54,514 49,127 +11.0%
Realized Investment Gains Losses -5,953 -6,069 +1.9%
Other Operating Activities Cash Flow Statement 684 652 +4.9%
Change in Accounts Receivable -22,124 -62,706 +64.7%
Change in Inventory -6,286 -11,907 +47.2%
Increase Decrease In Prepaid Taxes -12,389 -1,617 -666.2%
Change in Prepaid & Other Assets -2,270 -7,292 +68.9%
Increase Decrease In Lease Liability -578 -833 +30.6%
Change in Other Liabilities 2,280 1,419 +60.7%
Change in Accounts Payable 826 1,011 -18.3%
Increase Decrease In Accrued Rebates 21,268 30,827 -31.0%
Increase Decrease In Accrued Liabilities And Other Operating Liabilities 14,104 5,391 +161.6%
Increase Decrease Accrued Legal Settlement And In Process Research And Development -31,250 31,250 -200.0%
Net Cash from Operations 200,865 123,420 +62.7%
Deferred Income Taxes 27,275 — —
Investing Activities
Proceeds From Sale Of Property Plant And Equipment 435 — —
Capital Expenditures -11,951 -4,238 -182.0%
Purchases of Investments -422,540 -457,740 +7.7%
Proceeds From Sale Maturity And Collection Of Shortterm Investments 375,639 298,539 +25.8%
Net Cash from Investing -58,417 -163,439 +64.3%
Right Of Use Asset Obtained In Exchange For Operating Lease Liability 1,786 — —
Financing Activities
Proceeds From Stock Options Exercised 22,661 32,400 -30.1%
Tax Withholding for Share Compensation (FY) — — —
Show Award Type breakouts
Restricted Stock -1,812 -1,205 -50.4%
Restricted Stock Units RSU -12,144 -4,181 -190.5%
Net Cash from Financing 8,705 27,014 -67.8%
Supplemental
Unpaid Capital Expenditures 3,067 8,497 -63.9%
Income Taxes Paid 15,673 5,665 +176.7%
Income Taxes Paid 14,793 5,665 +161.1%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 286 -458 +162.4%
Net Change in Cash 151,439 -13,463 +1224.9%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 496,304 344,865 +43.9%

Values in thousands USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key